President Trump said Thursday that vaccines will start to be delivered next week and the week after.
Speaking to troops on a video link for Thanksgiving, he said that the first to get them would be front-line workers, medical personnel and senior citizens.
In the UK, the pharmaceutical company AstraZeneca is planning an extra global trial for its vaccine.
They're hoping to clear some unanswered questions for the world after the company said the positive results of its trials so far may have been affected by an error.
The company's CEO said on Thursday that AstraZeneca wants the extra study to confirm the 90-percent efficacy rate.
The additional trial is not expected to hold up approvals in the U.K. or the EU, and it's seen as a positive sign that the vaccine will ultimately be safe.
"The study they’ve shown does not mean that it has failed. It just means that we cannot use it because it did work for a lot of people who were injected with it. So the group that received two full doses that showed 62-percent of the efficacy, it still means that it’s usable, but with larger number of participants."
He recommended that the new study include at least 30-thousand participants.
Meanwhile, the South Korean government continues working to secure enough vaccines by negotiating with the companies behind all five existing candidates.
Officials say they'll disclose detailed information about vaccine supplies to the public as soon as possible hoping to do so by early December.
Choi Won-jong, Arirang News.